Results 61 to 70 of about 28,675 (247)

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Environmental enrichment alleviates the deleterious effects of stress in experimental autoimmune encephalomyelitis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Background Clinical observations support the hypothesis that stressful events increase relapse occurrence in multiple sclerosis patients, while stress-reduction strategies can modulate this effect.
Antoine Philippe Fournier, Erwan Baudron, Isabelle Wagnon, Philippe Aubert, Denis Vivien, Michel Neunlist, Isabelle Bardou, Fabian Docagne   +7 more
doaj   +1 more source

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Alisha Sharma, Alyssa Y. Li, Teruko Kishibe, Dennis Wong, Kevin M. Sanders, Maggie Jiang, Heedo Lee, Christine Song, Kieran Mcintyre, Christian Pagnoux, Yvonne Chan, John M. Lee, Daniel J. Lee   +12 more
wiley   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello, Mario Picozza, Gisella Guerrera, Silvia Corbisiero, Andrea Misiti, Roberta C. Placido, Alice Verdiani, Lorenzo de Marco, Manolo Sambucci, Elena Olivieri, Daniela F. Angelini, Esmeralda Quartuccio, Luca Prosperini, Carla Tortorella, Maria C. Buscarinu, Valeria Zancan, Francesca de Masi, Marco Salvetti, Claudio Gasperini, Giovanna Borsellino, Luca Battistini   +20 more
wiley   +1 more source

Guided Imagery Improves Mood, Fatigue, and Quality of Life in Individuals With Multiple Sclerosis: An Exploratory Efficacy Trial of Healing Light Guided Imagery

Journal of Evidence-Based Integrative Medicine, 2018
Multiple sclerosis is a disabling and progressive neurological disease that has significant negative effects on health-related quality of life. This exploratory efficacy study examined the effects of Healing Light Guided Imagery (HLGI), a novel variant ...
Laura K. Case PhD, Paula Jackson BSJ, Revere Kinkel MD, Paul J. Mills PhD   +3 more
doaj   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

New insights into the phenomenon of remissions and relapses in autoimmune diseases and the puzzle of benign autoantibodies in healthy individuals

Frontiers in Immunology
The onset and relapse of autoimmune diseases (AIDs) are triggered by autoimmune attacks on target tissues. However, symptoms are unlikely to appear if damaged cells are rapidly replaced.
Zeev Elkoshi
doaj   +1 more source

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Fingolimod is approved for the treatment of highly active relapsing–remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK.
Gordon Mazibrada, Charlotte Sharples, Ines Perfect   +2 more
doaj   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Epidemiology of Multiple Sclerosis in Fars Province

مجله اپیدمیولوژی ایران, 2014
Background & Objectives : Multiple Sclerosis is a chronic progressive disease with several disabilities for patients. Its distribution in the world can be an important clue to study racial, genetic, and environmental factors; thus, epidemiologic studies ...
S Izadi, AR Nikseresht, M Poursadeghfard
doaj